Canrenone

Oral
Hepatic diseases, Hypertension, Refractory oedema associated with heart failure

Hyperkalemia, hyponatremia, Addison's disease, severe renal impairment, pregnancy, lactation.

Elderly, DM, renal or hepatic impairment, porphyria, patients likely to develop acidosis. Monitor serum electrolytes and blood-urea-nitrogen.

Headache, drowsiness, GI disturbances, ataxia, mental confusion, skin rashes, gynecomastia, breast enlargement, hirsutism, deepening of the voice, menstrual irregularities, impotence, mild acidosis, lethargy, hyperkalaemia (discontinue), hyponatraemia, hepatotoxicity, osteomalacia, blood disorders.

Potassium supplements, other potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, trilostane. Lithium, thiazides, chlorpropamide, other antihypertensives, noradrenaline. Reduce ulcer-healing properties of carbenoxolone.

Transient increases in blood-urea-nitrogen concentrations.

Description:
Mechanism of Action: Canrenone acts on the distal portion of the renal tubule as a competitive antagonist of aldosterone. It increases sodium and water excretion and reduces potassium excretion.

Diuretics